{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:49:46Z","timestamp":1769831386432,"version":"3.49.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["OCH # 126275"],"award-info":[{"award-number":["OCH # 126275"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004828","name":"Grand Challenges Canada","doi-asserted-by":"publisher","award":["S5 386-01"],"award-info":[{"award-number":["S5 386-01"]}],"id":[{"id":"10.13039\/501100004828","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>In the context of the current COVID-19 pandemic, there is still limited information about how people suffering from autoimmune diseases respond to the different COVID vaccines. The fact that they are taking an immunosuppressant or other drugs that aim to decrease the immune system activities, such as hydroxychloroquine (HCQ), could also impact their ability to respond to a COVID vaccine and vaccines in general.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Heathy donors were given 200mg of HCQ daily for 6-weeks to assess HCQs impact on the systemic T cells and humoral immune response. Peripheral blood mononuclear cells (PBMC) and plasma were obtained at baseline and 6-weeks after starting daily HCQ. Flow cytometry assays were designed to determine changes in T cell activation and T cell responses. Bead array multiplex were used to analyse antibodies and cytokine levels before and after HCQ intake.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>As anticipated, HCQ treatment decreased <jats:italic>ex vivo<\/jats:italic> T cell activation. We observed a decrease in CD4<jats:sup>+<\/jats:sup>CD161<jats:sup>-<\/jats:sup> expressing CCR5 (p = 0.015) and CD69 (p = 0.004) as well as in CD8<jats:sup>+<\/jats:sup>CCR5<jats:sup>+<\/jats:sup> (p = 0.003), CD8<jats:sup>+<\/jats:sup>CD161<jats:sup>+<\/jats:sup>CCR5<jats:sup>+<\/jats:sup> (p = 0.002) and CD8<jats:sup>+<\/jats:sup>CD161<jats:sup>+<\/jats:sup>CD95<jats:sup>+<\/jats:sup> (p = 0.004). Additionally, HCQ decreased the proportion of Th17 expressing CD29 (p = 0.019), a subset associated with persistent inflammation. The proportion of T regulatory cells expressing the inhibitory molecule TIGIT was also reduced by HCQ (p = 0.003). As well, T cells from people on HCQ were less responsive to activation and cytokine production following stimulation with recall antigens and memory T cells were less likely to produce both IFN\u03b3 and TNF\u03b1 following stimulation.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This study shows HCQ is associated with lower T cell activation and decreased T cell cytokine production. While this study was not performed with the intent of looking at COVID vaccine response, it does provide important information about the changes in immune response that may occur in patient taking HCQ as a treatment for their autoimmune disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0287738","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T17:35:47Z","timestamp":1690997747000},"page":"e0287738","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hydroxychloroquine reduces T cells activation recall antigen responses"],"prefix":"10.1371","volume":"18","author":[{"given":"Monika M.","family":"Kowatsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Lajoie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Mwangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Omollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius","family":"Oyugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Hollett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Kimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8227-6649","authenticated-orcid":true,"given":"Keith R.","family":"Fowke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"issue":"7","key":"pone.0287738.ref001","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/S2352-3018(22)00097-2","article-title":"Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19","volume":"9","author":"S Bertagnolio","year":"2022","journal-title":"Lancet HIV"},{"key":"pone.0287738.ref002","first-page":"1","article-title":"Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study","volume":"58","author":"GBET Al","year":"2021","journal-title":"Eur Respir J"},{"key":"pone.0287738.ref003","first-page":"1","article-title":"Pre \u2011 existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID \u2011 19","author":"O Gallagher","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"pone.0287738.ref004","first-page":"1","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta- \u00ad analysis","author":"S Akiyama","year":"2020","journal-title":"BMJ Autoinflammatory Disord"},{"issue":"January","key":"pone.0287738.ref005","first-page":"88","article-title":"Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis","volume":"162","author":"A Sakuraba","year":"2020","journal-title":"Gastroenterology"},{"issue":"11","key":"pone.0287738.ref006","article-title":"Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases","volume":"7","author":"in patients with immune-mediated inflammatory diseases","year":"2022","journal-title":"JCI insight"},{"issue":"5","key":"pone.0287738.ref007","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"KD Rainsford","year":"2015","journal-title":"Inflammopharmacology"},{"issue":"5","key":"pone.0287738.ref008","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bcp.12872","article-title":"Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis","volume":"81","author":"YC Kaplan","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"pone.0287738.ref009","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19","volume":"383","author":"D Boulware","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0287738.ref010","article-title":"Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19","volume":"173","author":"A V Hernandez","year":"2020","journal-title":"Ann Intern Med"},{"key":"pone.0287738.ref011","article-title":"Three big studies dim hopes that hydroxychloroquine can treat or prevent COVID-19","author":"K. Kupferschmidt","year":"2020","journal-title":"Science (80-)"},{"issue":"1","key":"pone.0287738.ref012","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2665-9913(20)30378-7","article-title":"Articles Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform","volume":"3","author":"CT Rentsch","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"pone.0287738.ref013","doi-asserted-by":"crossref","first-page":"e25150","DOI":"10.1002\/jia2.25150","article-title":"Using safe, affordable and accessible non-steroidal anti-inflammatory drugs to reduce the number of HIV target cells in the blood and at the female genital tract","volume":"21","author":"J Lajoie","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"pone.0287738.ref014","first-page":"1801","article-title":"Development of polyether urethane intravaginal rings for the sustained delivery of hydroxychloroquine","volume":"8","author":"Y Chen","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"pone.0287738.ref015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1155\/2011\/202516","article-title":"Evaluation of influenza-specific humoral response by microbead array analysis","volume":"22","author":"Y Keynan","year":"2011","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"pone.0287738.ref016","unstructured":"ThermoFisher Scientific. BestProtocols: Staining Intracellular Antigens for Flow Cytometry\u2014CA [Internet]. ThermoFisher Scientific; [cited 2020 Apr 8]. https:\/\/www.thermofisher.com\/ca\/en\/home\/references\/protocols\/cell-and-tissue-analysis\/protocols\/staining-intracellular-antigens-flow-cytometry.html"},{"issue":"5","key":"pone.0287738.ref017","doi-asserted-by":"crossref","first-page":"e36651","DOI":"10.1371\/journal.pone.0036651","article-title":"Anti-HPV16 E2 protein T-cell responses and viral control in women with usual vulvar intraepithelial neoplasia and their healthy partners","volume":"7","author":"S Jacobelli","year":"2012","journal-title":"PLoS One"},{"key":"pone.0287738.ref018","article-title":"The role of CD4 and CD8 T cells in viral infections","author":"UH Koszinowski","year":"1991","journal-title":"Current Opinion in Immunology"},{"issue":"6593","key":"pone.0287738.ref019","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa","volume":"376","author":"JRC Pulliam","year":"2022","journal-title":"Science (80-)"},{"issue":"7","key":"pone.0287738.ref020","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"A Grifoni","year":"2020","journal-title":"Cell"},{"issue":"1","key":"pone.0287738.ref021","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1038\/s41467-021-25312-0","article-title":"Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery","volume":"12","author":"C Feng","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"pone.0287738.ref022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2005.09.034","article-title":"1. Overview of the human immune response","volume":"117","author":"DD Chaplin","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"pone.0287738.ref023","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"OJ Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pone.0287738.ref024","doi-asserted-by":"crossref","first-page":"e2212073","DOI":"10.1001\/jamanetworkopen.2022.12073","article-title":"Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine","volume":"5","author":"R Lassauni\u00e8re","year":"2022","journal-title":"JAMA Netw open"},{"issue":"3","key":"pone.0287738.ref025","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination","volume":"28","author":"SMS Cheng","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"pone.0287738.ref026","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/v13030422","article-title":"Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection","volume":"13","author":"F Gobbi","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"pone.0287738.ref027","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/AOG.0000000000004438","article-title":"Antibody Response to Coronavirus Disease 2019 (COVID-19) Messenger RNA Vaccination in Pregnant Women and Transplacental Passage Into Cord Blood","volume":"138","author":"M Prabhu","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"20","key":"pone.0287738.ref028","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"LA Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0287738.ref029","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1093\/cid\/ciaa461","article-title":"Antibody Detection and Dynamic Characteristics in Patients With Coronavirus Disease 2019","volume":"71","author":"F Xiang","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pone.0287738.ref030","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"QX Long","year":"2020","journal-title":"Nat Med"},{"issue":"16","key":"pone.0287738.ref031","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019","volume":"71","author":"J Zhao","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0287738.ref032","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12026-016-8812-z","article-title":"Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome","volume":"65","author":"E Nuri","year":"2017","journal-title":"Immunol Res"},{"key":"pone.0287738.ref033","author":"ILA Bodewes","journal-title":"Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sj\u00f6gren\u2019s syndrome in the JOQUER randomized trial"},{"issue":"12","key":"pone.0287738.ref034","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-01-329060","article-title":"Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy\u2013treated immunologic nonresponders","volume":"118","author":"S Piconi","year":"2011","journal-title":"Blood"},{"issue":"7821","key":"pone.0287738.ref035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"N Le Bert","year":"2020","journal-title":"Nature"},{"issue":"2","key":"pone.0287738.ref036","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4049\/jimmunol.1402990","article-title":"Polyfunctional, Pathogenic CD161+ Th17 Lineage Cells Are Resistant to Regulatory T Cell-Mediated Suppression in the Context of Autoimmunity","volume":"195","author":"SA Basdeo","year":"2015","journal-title":"J Immunol"},{"issue":"1","key":"pone.0287738.ref037","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cyto.2015.02.002","article-title":"The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis","volume":"74","author":"SMJ Paulissen","year":"2015","journal-title":"Cytokine"},{"issue":"11","key":"pone.0287738.ref038","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1002\/art.34601","article-title":"Modulation of STAT-3 in Rheumatoid Synovial T Cells Suppresses Th17 Differentiation and Increases the Proportion of Treg Cells","volume":"64","author":"JH Ju","year":"2012","journal-title":"ARTHRITIS Rheum"},{"issue":"12","key":"pone.0287738.ref039","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/art.1780351209","article-title":"RHEUMATOID SYNOVIUM IS ENRICHED IN CD45RBdim MATURE MEMORY T CELLS THAT ARE POTENT HELPERS FOR B CELL DIFFERENTIATION","volume":"35","author":"R Thomas","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"11","key":"pone.0287738.ref040","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1182\/blood.V95.11.3460","article-title":"Hydroxychloroquine inhibits calcium signals in T cells: A new mechanism to explain its immunomodulatory properties","volume":"95","author":"FD Goldman","year":"2000","journal-title":"Blood"},{"key":"pone.0287738.ref041","first-page":"1","article-title":"Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation","volume":"7","author":"RLJ Schmidt","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0287738.ref042","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/clim.2000.4957","article-title":"CXCR3 and CCR5 ligands in rheumatoid arthritis synovium","volume":"98","author":"DD Patel","year":"2001","journal-title":"Clin Immunol"},{"issue":"1","key":"pone.0287738.ref043","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41231-020-00066-x","article-title":"C-C chemokine receptor type 5 links COVID-19, rheumatoid arthritis, and Hydroxychloroquine: in silico analysis","volume":"5","author":"MY Hachim","year":"2020","journal-title":"Transl Med Commun"},{"issue":"3","key":"pone.0287738.ref044","first-page":"2627","article-title":"CD4+CD29+T cells are blamed for the persistent inflammatory response in ulcerative colitis","volume":"8","author":"Y Zhu","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"11","key":"pone.0287738.ref045","doi-asserted-by":"crossref","first-page":"7791","DOI":"10.4049\/jimmunol.179.11.7791","article-title":"An IL-17F\/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment","volume":"179","author":"SC Liang","year":"2007","journal-title":"J Immunol"},{"key":"pone.0287738.ref046","author":"S Maeda Id","year":"2019","journal-title":"Circulating Th17.1 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: An exploratory research"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0287738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T17:36:30Z","timestamp":1690997790000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0287738"}},"subtitle":[],"editor":[{"given":"Janin","family":"Nouhin","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0287738","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]}}}